Svetlana Lukienko / Shutterstock.com
UK-based diagnostics company Oxford Immunotec has announced that it will acquire Imugen, a US clinical laboratory, for $22.2 million in cash.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Oxford Immunotec, Imugen, tick-borne disease, immune system, mergers and acquisitions